SG Americas Securities LLC Has $573,000 Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX)

SG Americas Securities LLC boosted its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 921.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 395,017 shares of the company's stock after buying an additional 356,352 shares during the quarter. SG Americas Securities LLC owned approximately 0.29% of Compass Therapeutics worth $573,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in shares of Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company's stock valued at $141,000 after purchasing an additional 70,200 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Compass Therapeutics in the 2nd quarter valued at about $41,000. Rovin Capital UT ADV acquired a new position in Compass Therapeutics in the 3rd quarter valued at about $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics in the 3rd quarter valued at about $30,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Compass Therapeutics during the third quarter worth approximately $79,000. Institutional investors own 68.43% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Leerink Partnrs downgraded Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th. Leerink Partners lowered Compass Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $5.00 to $4.00 in a report on Friday, November 15th. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, D. Boral Capital reissued a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $11.80.

Compass Therapeutics Price Performance

Compass Therapeutics stock traded up $0.04 during mid-day trading on Tuesday, reaching $3.12. 575,507 shares of the company were exchanged, compared to its average volume of 2,634,088. The firm has a market cap of $429.28 million, a PE ratio of -8.43 and a beta of 1.15. The company has a fifty day simple moving average of $1.96 and a 200-day simple moving average of $1.67. Compass Therapeutics, Inc. has a 12 month low of $0.76 and a 12 month high of $3.63.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. Sell-side analysts anticipate that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current year.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.